keyword
https://read.qxmd.com/read/38656971/gut-microbiota-composition-in-patients-with-crohn-s-disease-in-saudi-arabia
#1
JOURNAL ARTICLE
Hadil Alahdal, Ghaida Almuneef, Manal Muhammed Alkhulaifi, Omar Aldibasi, Abdulrahman Aljouie, Othman Alharbi, Zakiah Naser Almohawes, Fatemah Basingab, Mokhtar Rejili
Crohn's disease (CD) entails intricate interactions with gut microbiome diversity, richness, and composition. The relationship between CD and gut microbiome is not clearly understood and has not been previously characterized in Saudi Arabia. We performed statistical analysis about various factors influencing CD activity and microbiota dysbiosis, including diagnosis, treatment, and its impact on their quality of life as well as high-throughput metagenomic V3-V4 16S rRNA encoding gene hypervariable region of a total of eighty patients with CD, both in its active and inactive state with healthy controls...
2024: PloS One
https://read.qxmd.com/read/38656784/intravenous-versus-subcutaneous-infliximab-in-inflammatory-bowel-disease-a-systematic-review-and-meta-analysis
#2
JOURNAL ARTICLE
John David Chetwood, Yvonne Tran, Sreedhar Subramanian, Philip J Smith, Marisa Iborra, Anthony Buisson, Sudarshan Paramsothy, Rupert W Leong
BACKGROUND: Subcutaneous (SC) infliximab may provide multiple benefits over intravenous (IV) formulations. However, studies for efficacy and safety in inflammatory bowel disease (IBD) have been constrained by small sizes that limit the interpretation of outcomes, especially for subgroups potentially at high-risk of disease relapse. METHODS: We conducted a systematic review and random-effects meta-analysis up to January 2023 to evaluate the change in clinical remission after transitioning from IV to SC infliximab in patients with IBD in clinical remission...
April 24, 2024: Journal of Crohn's & Colitis
https://read.qxmd.com/read/38656421/pneumocystis-jirovecii-pneumonia-complicating-use-of-upadacitinib-in-a-patient-with-ulcerative-colitis-and-primary-sclerosing-cholangitis-a-case-report
#3
JOURNAL ARTICLE
Simone Chin, Lucy Fox, Avik Majumdar, Mark Oliver, Matthew C Choy, Peter De Cruz
No abstract text is available yet for this article.
April 24, 2024: Inflammatory Bowel Diseases
https://read.qxmd.com/read/38656368/imaging-and-clinical-predictors-of-surgery-in-stricturing-ileal-crohn-s-disease-a-retrospective-study-from-a-large-pediatric-hospital
#4
JOURNAL ARTICLE
Pradipta Debnath, Katherine N Epstein, Murat Kocaoglu, Alexander J Towbin, Lee A Denson, Jonathan R Dillman
PURPOSE: (1) To determine the frequency of surgical management in children with Crohn's Disease (CD) and a new radiologic ileal stricture, and (2) to identify imaging and clinical features that predict the need for surgery. METHODS: This retrospective study included pediatric patients (< 21 years old) with CD and a new ileal stricture diagnosed by MRE, CTE, or CT between July 2018 and June 2023. Three board-certified radiologists recorded stricture length, maximum mural thickness, minimum lumen diameter, maximum upstream diameter, and simplified magnetic resonance index of activity (sMaRIA) score...
April 24, 2024: Abdominal Radiology
https://read.qxmd.com/read/38656269/successful-guselkumab-treatment-of-a-refractory-psoriasis-patient-with-graves-disease-a-case-report
#5
JOURNAL ARTICLE
Xinyi Shao, Kun Huang, Aijun Chen, Chuan Liu, Jianxia Xiong, Yun Pan, Xiaoli Chen, Ping Wang
Psoriasis is a chronic inflammatory skin disease. It is associated with many autoimmune diseases such as rheumatoid arthritis, Crohn's disease and thyroid diseases. Graves' disease (GD) is a common organ-specific autoimmune disease characterized by diffuse goitre and thyrotoxicosis. Management of psoriasis patients with GD is challenging. This current report presents the case of a 34-year-old female patient with refractory psoriasis with GD who was hospitalized for drug eruption and then experienced new-onset erythema and scaling following treatment with adalimumab and secukinumab...
April 2024: Journal of International Medical Research
https://read.qxmd.com/read/38655866/efficacy-of-dose-escalation-of-oral-5-aminosalicylic-acid-for-ulcerative-colitis-with-a-mayo-endoscopic-subscore-of-1-an-open-label-randomized-controlled-trial
#6
JOURNAL ARTICLE
Tomohiro Fukuda, Yasuhiro Aoki, Hiroki Kiyohara, Ayumi Yokoyama, Atsushi Nakazawa, Yusuke Yoshimatsu, Shinya Sugimoto, Kosaku Nanki, Yohei Mikami, Kayoko Fukuhara, Shinta Mizuno, Tomohisa Sujino, Makoto Mutaguchi, Kaoru Takabayashi, Yuichi Morohoshi, Yasuo Hosoda, Haruhiko Ogata, Yasushi Iwao, Makoto Naganuma, Takanori Kanai
BACKGROUND: Endoscopic healing is generally defined as Mayo endoscopic subscore (MES) ≤1 in ulcerative colitis (UC). However, patients with an MES of 1 are at higher relapse risk than those with an MES of 0. This study evaluated the therapeutic efficacy of proactive dose escalation of oral 5-aminosalicylic acid (5-ASA) in UC patients with an MES of 1. METHODS: An open-label, randomized controlled trial was conducted in 5 hospitals between 2018 and 2022. Ulcerative colitis patients in clinical remission under oral 5-ASA therapy and diagnosed as having an MES of 1 were enrolled...
April 24, 2024: Inflammatory Bowel Diseases
https://read.qxmd.com/read/38655853/systematic-review-and-meta-analysis-impact-of-depression-on-prognosis-in-inflammatory-bowel-disease
#7
REVIEW
Yuejin Ji, Hongxiao Li, Guoliang Dai, Xu Zhang, Wenzheng Ju
BACKGROUND AND AIM: Depression is highly prevalent in patients with inflammatory bowel disease (IBD), which may affect the prognosis of IBD. This aimed to investigate the impact of depression on prognosis in IBD. METHODS: A systematic literature search was performed in four databases (Medline, Embase, Web of Science, and PsycINFO) up to December 31, 2023. Studies were included if they investigated the impact of depression on prognosis in IBD. The primary outcome was flare in IBD, and secondary outcomes were hospitalization, readmission, emergency visits, surgery, and escalation of medical therapy...
April 24, 2024: Journal of Gastroenterology and Hepatology
https://read.qxmd.com/read/38655569/vaginal-delivery-in-women-with-perianal-crohn-s-disease-why-not
#8
JOURNAL ARTICLE
Irene J Schaafsma, Froukje J Hoogenboom, Gerard Dijkstra, Jelmer R Prins, Marijn C Visschedijk
BACKGROUND: Pregnant women with active perianal Crohn's disease indicate a cesarean delivery according to the current European Crohn's and Colitis Organisation guidelines. This advice is based on the assumption that vaginal delivery leads to exacerbation of perianal disease and worsening of fecal continence. However, there is no strong evidence to support this. OBJECTIVE: This study aims to examine the effects of the delivery method on perianal disease progression and fecal incontinence in women with perianal Crohn's disease...
May 2024: AJOG global reports
https://read.qxmd.com/read/38655181/antibiotics-influence-the-risk-of-anti-drug-antibody-formation-during-anti-tnf-therapy-in-chinese-inflammatory-bowel-disease-patients
#9
JOURNAL ARTICLE
Meng Sun, Jingyi Ju, Hongzhen Xu, Mengqi Luo, Zhaoyang Li, Yufang Wang
Aims: The formation of anti-drug antibodies (ADAs) during anti-tumor necrosis factor (anti-TNF) therapy is reported to lead to reducing serum drug levels, which may bring about a loss of response to treatment. Previous research has suggested an association between specific antibiotic classes and ADA formation during anti-TNF therapy. However, there are few studies specifically examining this association in Chinese inflammatory bowel disease (IBD) patients. Therefore, our study aimed to evaluate the possible effect of antibiotic use on ADA formation to anti-TNF therapy in Chinese patients with IBD...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38655034/long-term-real-world-data-of-ustekinumab-in-crohn-s-disease-the-stockholm-ustekinumab-study
#10
JOURNAL ARTICLE
Francesca Bello, Samer Muhsen, Haider Sabhan, Alexandra Borin, Fredrik Johansson, Charlotte Höög, Ole Forsberg, Christina Wennerström, Charlotte Söderman, Mikael Lördal, Sven Almer
BACKGROUND: Ustekinumab is used to treat inflammatory bowel disease mainly in patients failing anti-tumour necrosis factor (TNF)-agents. OBJECTIVES: To provide real-world data in unselected patients with Crohn's disease (CD), treated with ustekinumab. DESIGN: Longitudinal retrospective study at four hospitals in Stockholm, Sweden. METHODS: Disease activity (Harvey-Bradshaw index and physician global assessment), laboratory parameters, endoscopic findings and drug persistence were assessed...
2024: Therapeutic Advances in Gastroenterology
https://read.qxmd.com/read/38653907/contributions-of-synthetic-chemicals-to-autoimmune-disease-development-and-occurrence
#11
REVIEW
Noelle N Kosarek, Emma V Preston
PURPOSE OF REVIEW: Exposure to many synthetic chemicals has been linked to a variety of adverse human health effects, including autoimmune diseases. In this scoping review, we summarize recent evidence detailing the effects of synthetic environmental chemicals on autoimmune diseases and highlight current research gaps and recommendations for future studies. RECENT FINDINGS: We identified 68 recent publications related to environmental chemical exposures and autoimmune diseases...
April 24, 2024: Current Environmental Health Reports
https://read.qxmd.com/read/38653566/safety-of-biologics-and-small-molecules-for-inflammatory-bowel-diseases-in-organ-transplant-recipients
#12
JOURNAL ARTICLE
Ga Hee Kim, Minjun Kim, Kyuwon Kim, Jung-Bin Park, Ji Eun Baek, June Hwa Bae, Seung Wook Hong, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sang Hyoung Park
PURPOSE: This study aimed to evaluate the safety of biologics and small molecules for the treatment of inflammatory bowel diseases (IBD) in patients receiving antirejection therapies after organ transplants. MATERIALS AND METHODS: We reviewed the medical records of patients with IBD who received organ transplants at the Asan Medical Center between January 1989 and December 2021. We compared the parameters of patients receiving biologics or small molecules to those of patients without those therapies...
May 2024: Yonsei Medical Journal
https://read.qxmd.com/read/38653187/huc-mscs-therapy-for-crohn-s-disease-efficacy-in-tnbs-induced-colitis-in-rats-and-pilot-clinical-study
#13
JOURNAL ARTICLE
Qinjuan Sun, Shan Li, Ritian Lin, Guangxi Zhao, Jinlai Lu, Bin Liu, Miao Hu, Wei Wang, Xiaoqing Yang, Yushuang Wei, Wenwen Jia, Yanni Hu, Wei Zhang, Jiawen Zhu, Daxiang Cui, Lan Zhong
BACKGROUND: The use of mesenchymal stem cells (MSCs) has recently emerged as a promising new therapeutic strategy for many diseases including perianal fistulizing Crohn's disease (CD). Whether hUC-MSCs can promote the healing of luminal ulcer in CD has not been studied so far. METHODS: The model of TNBS-induced colitis in rats was used to confirm the efficacy of hUC-MSCs in the treatment of CD. Then, seventeen CD patients refractory to or unsuitable for currently available therapies were enrolled and received once submucosal local injection through colonoscopy combined with once intravenous drip on the next day...
April 22, 2024: EBioMedicine
https://read.qxmd.com/read/38652376/mycobacterium-marinum-infection-in-a-patient-with-crohn-s-disease-on-anti-tumor-necrosis-factor-treatment
#14
JOURNAL ARTICLE
Marilena Tooulia, Aristotelis Mellos, Ioannis Vougadiotis, Spyridon Vrakas
No abstract text is available yet for this article.
April 23, 2024: Indian Journal of Gastroenterology: Official Journal of the Indian Society of Gastroenterology
https://read.qxmd.com/read/38652172/a-randomized-controlled-trial-of-two-hepatitis-a-vaccine-doses-among-adolescents-with-juvenile-idiopathic-arthritis-and-crohn-s-disease-on-immunosuppressive-therapy-a-pilot-study
#15
JOURNAL ARTICLE
Racheal Githumbi, Susan Kuhn, Carla Osiowy, Jacqueline Day, Jennifer C C deBruyn, Marvin J Fritzler, Nicole A Johnson, Otto Vanderkooi, Heinrike Schmeling
This pilot randomized controlled trial assessed the immunogenicity of paediatric versus adult Hepatitis A vaccine doses in immunosuppressed adolescents (12-15 years) with Juvenile Idiopathic Arthritis and Crohn's Disease. The study aimed to assess if a single, higher dose provides better immunogenicity, particularly beneficial before travel.
April 23, 2024: Journal of Travel Medicine
https://read.qxmd.com/read/38651771/meta-analysis-persistence-of-advanced-therapies-in-the-treatment-of-inflammatory-bowel-disease
#16
REVIEW
Tsz Hong Yiu, Yanna Ko, Aviv Pudipeddi, Patrizia Natale, Rupert W Leong
BACKGROUND: The expanding options in advanced therapies for ulcerative colitis (UC) and Crohn's disease (CD) present challenges in treatment selection. Persistence analysis assesses drug durability in real-world settings, acting as a surrogate marker for medication efficacy and tolerance. Unlike traditional comparative studies, persistence analysis provides insights extending beyond the initial year of treatment. AIM: To provide real-world evidence on treatment effectiveness, tolerability and preferences of physicians and patients regarding various advanced therapies for IBD...
April 23, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38651743/predictors-of-irritable-bowel-syndrome-like-symptoms-in-quiescent-inflammatory-bowel-disease
#17
JOURNAL ARTICLE
Mehwish Ahmed, Autumn Pu, Kara Jencks, Shrinivas Bishu, Peter Higgins, William D Chey, Krishna Rao, Allen Lee
BACKGROUND: Many patients with quiescent inflammatory bowel disease (IBD) suffer from irritable bowel syndrome (IBS)-like symptoms. Although these symptoms cause significant reductions in quality of life, evidence-based treatments are lacking as risk factors and pathophysiology of these symptoms are not clearly defined. We aimed to identify risk factors for development of IBS-like symptoms in IBD patients with quiescent disease. METHODS: We performed a single-center retrospective cohort study of adults with IBD from 2015 to 2021...
April 23, 2024: Neurogastroenterology and Motility: the Official Journal of the European Gastrointestinal Motility Society
https://read.qxmd.com/read/38651614/risk-factors-for-surgery-in-stricturing-small-bowel-crohn-s-disease-a-retrospective-cohort-study-from-the-getaid-p%C3%A3-diatrique
#18
JOURNAL ARTICLE
Edouard Lacotte, Louis Boujonnier, Christine Martinez-Vinson, Jérôme Viala, Delphine Ley, Stéphanie Coopman, Héloïse Lerisson, Alain Dabadie, Clémentine Dumant-Forrest, Bénédicte Pigneur, Frank Ruemmele, Raphael Enaud, Aurélie Comte, Julie Rebeuh, Valérie Bertrand, Nicolas Caron, Anne Breton, Rémi Duclaux-Loras, Ioana Vasies, Claire Dupont-Lucas
OBJECTIVES: Previous studies have shown rates of surgical resection of up to 41% in stricturing pediatric Crohn's disease. In this retrospective multicenter study, our aims were to identify clinical risk factors and magnetic resonance enterography (MRE) features of small bowel strictures associated with surgery. METHODS: Pediatric patients with symptomatic stricturing small bowel CD (defined as obstructive symptoms or proximal dilatation on MRE) confirmed by MRE between 2010 and 2020 were recruited from 12 French tertiary hospitals...
April 23, 2024: Journal of Pediatric Gastroenterology and Nutrition
https://read.qxmd.com/read/38650481/magnetic-resonance-enterography-findings-46%C3%A2-weeks-after-initiation-of-biological-therapy-predict-long-term-adverse-outcomes-in-crohn-s-disease
#19
JOURNAL ARTICLE
Agnès Fernández-Clotet, Ingrid Ordás, Maria Carme Masamunt, Berta Caballol, Sonia Rodríguez, Marta Gallego, Rebeca Barastegui, Anny Carolina Saavedra, Julián Panés, Elena Ricart, Jordi Rimola
BACKGROUND AND AIMS: Magnetic resonance enterography (MRE) depicts transmural changes in response to biological treatment for Crohn's disease (CD); however, the long-term prognostic significance of these findings is unknown. The primary objective of this study was to identify findings on MRE 46 weeks after initiating biological treatment that predict adverse long-term outcomes. METHODS: Patients with CD underwent MRE 46 weeks after initiating biological treatment and were prospectively followed for 2 years...
April 23, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38648495/fecal-microbiota-is-associated-with-extraintestinal-manifestations-in-inflammatory-bowel-disease
#20
JOURNAL ARTICLE
Sandra Hertz, Jacqueline Moltzau Anderson, Hans Linde Nielsen, Claire Schachtschneider, Kathryn E McCauley, Mustafa Özçam, Lone Larsen, Susan V Lynch, Henrik Nielsen
INTRODUCTION: A large proportion of patients with inflammatory bowel disease (IBD) experience IBD-related inflammatory conditions outside of the gastrointestinal tract, termed extraintestinal manifestations (EIMs) which further decreases quality of life and, in extreme cases, can be life threatening. The pathogenesis of EIMs remains unknown, and although gut microbiota alterations are a well-known characteristic of patients with IBD, its relationship with EIMs remains sparsely investigated...
December 2024: Annals of Medicine
keyword
keyword
25823
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.